IDXX

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Terry SmithFundsmith $824M1.5M shares TrimQ1 2026 $446M $561.89 $550.99
Polen CapitalInvestor $391M695.8k shares TrimQ1 2026 $259M $561.89 $550.99
Ron BaronBaron Capital $918M1.6M shares TrimQ1 2026 $299M $561.89 $550.99

Congress Trades

Actor	Trade Size	Last Transaction	Amount Range	Price	Current Price
Ro KhannaDemocrat $8.0k13.9 shares BuyApr 13, 2026 $1k-$15k $574.00 $550.99
Byron DonaldsRepublican $8.0k12.5 shares BuySep 4, 2025 $1k-$15k $640.44 $550.99

News

zacks.comHere's Why Idexx Laboratories (IDXX) is a Strong Growth Stockzacks.comJun 9

zacks.comIdexx (IDXX) Down 3.2% Since Last Earnings Report: Can It Rebound?zacks.comJun 4

marketbeat.comIDEXX Laboratories Touts AI Push, inVue Dx Momentum at Stifel Conferencemarketbeat.comMay 30

seekingalpha.comIDEXX Laboratories, Inc. (IDXX) Presents at Stifel Jaws & Paws Conference 2026 Transcriptseekingalpha.comMay 27

businesswire.comIDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detectionbusinesswire.comMay 26

Trade IDXX

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

CEO: Jonathan J. Mazelsky
IPO Date: Jun 21, 1991

Market Data

Open: $563.55
High: $581.47
Low: $559.08
Volume: 418.2K
52W High: $769.98
52W Low: $506.91

Valuation

Market Cap: $46B
Enterprise Value: $47B

Financials

Free Cash Flow: $1.1B
Revenue: $4.3B
Net Income: $1.1B
Cash: $180M
Debt: $1.1B

Events

EarningsAug 3

EPS est. 3.95